AVITA Medical, Inc. (RCEL)

Market Cap	131.72M -41.9%
Revenue (ttm)	72.40M +20.6%
Net Income	-48.56M
EPS	-1.81
Shares Out	30.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	436,510
Open	4.240
Previous Close	4.240
Day's Range	4.010 - 4.320
52-Week Range	3.220 - 11.250
Beta	1.80
Analysts	Buy
Price Target	7.17 (+66.74%)
Earnings Date	Feb 12, 2026

About RCEL

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Cary Vance
• Employees: 260
• Stock Exchange: NASDAQ
• Ticker Symbol: RCEL
• Website: https://avitamedical.com

Financial Performance

In 2024, AVITA Medical's revenue was $64.25 million, an increase of 28.14% compared to the previous year's $50.14 million. Losses were -$61.85 million, 74.8% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for RCEL stock is "Buy." The 12-month stock price target is $7.17, which is an increase of 66.74% from the latest price.

Price Target

$7.17

(66.74% upside)

Analyst Consensus: Buy